
|Articles|January 24, 2005
BREAKING NEWS...
The black eye the FDA received recently over its handling of Vioxx (rofecoxib, Merck) and antidepressants hasn't slowed the agency's new drug approval rate for 2004. It cleared 31 new molecular entities (NMEs) last year, up from 21 in 2003.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Retatrutide Delivers Weight Loss, A1C Improvements in Additional Trials
2
FDA Approves First Fixed-Dose OTC of Acetaminophen and Naproxen
3
FDA Approves First-in-Class Centanafadine for Treatment of ADHD
4
Pharmacies Successfully Scale Paid SDOH Services Through Medicaid
5

























